Figure 4
From: An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology
Effect of mutation on predicted CTR/RAMP1 interface residues. Homology model of the isolated CTR (blue) (a) or the CTR/RAMP1 complex (CTR, blue; RAMP1, pink) (b). Insets are graphs of the change in rAmy (rat amylin) cAMP potency (pEC50) at either the CT(a) (a) or AMY1(a) (b) receptors compared with WT. Mutated residues (Q52, Y53 and Y56 in CTR, and Y66, H97 and F101 in RAMP1) are displayed in x-stick and CPK and coloured according to the magnitude of effect of mutation on peptide function (orange, 10–50-fold decreased potency; yellow, <10-fold decreased potency; and blue, not significantly different). Data points are mean±s.e.m., combined from four to six independent experiments, performed in duplicate or triplicate.
